Correlation between gliotoxin production and virulence of Aspergillus fumigatus in Galleria mellonella by Reeves, Emer P. et al.
Mycopathologia 158: 73–79, 2004.
© 2004 Kluwer Academic Publishers. Printed in the Netherlands. 73
Correlation between gliotoxin production and virulence of Aspergillus
fumigatus in Galleria mellonella
Emer P. Reeves1, C.G.M. Messina2, S. Doyle1 & K. Kavanagh1
1Department of Biology, National Institute for Cellular Biotechnology, National University of Ireland Maynooth,
County Kildare, Ireland; 2Laboratory of Haematology and Oncology, Instituto Superiore di Sanita, Viale Regina
Elena 299, 00161 Roma, Italy
Received 13 June 2003; accepted in final form 27 Octobber 2003
Abstract
Aspergillus fumigatus is a pathogenic fungus capable of causing both allergic lung disease and invasive aspergil-
losis, a serious, life-threatening condition in neutropenic patients. Aspergilli express an array of mycotoxins and
enzymes which may facilitate fungal colonisation of host tissue. In this study we investigated the possibility of
using the insect, Galleria mellonella, for in vivo pathogenicity testing of Aspergillus species. Four clinical isolates
of Aspergillus fumigatus and a single strain of Aspergillus niger were characterised for catalase and elastase activity
and for the production of gliotoxin. Gliotoxin is an immunosuppressive agent previously implicated in assisting
tissue penetration. Results illustrated a strain dependent difference in elastase activity but no significant difference
in catalase activity. Gliotoxin production was detected in vitro and in vivo by Reversed Phase-High Performance
Liquid Chromatography, with highest amounts being produced by A. fumigatus ATCC 26933 (350 ng/mg hyphae).
Survival probability plots (Kaplan–Meier) of experimental groups infected with Aspergillus conidia indicate that
G. mellonella is more susceptible to fungal infection by A. fumigatus ATCC 26933, implicating a critical role for
gliotoxin production rather than growth rate or enzymatic activity in the virulence of A. fumigatus in this model.
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Abbreviations: Aspergillus fumigatus, A. fumigatus; Galleria mellonella, G. mellonella; Minimal Essential
Medium Eagle, MEM; High Performance Liquid Chromatography, HPLC; Malt Extract Agar, MEA.
Introduction
Fungal infections are of increasing importance in
severely neutropenic and immunosuppressed patients
because of their high incidence and the associated high
mortality rate. Despite the development of triazole
anti-fungals and amphotericin B formulations the mor-
tality associated with fungal infection remains high
at 60–90%. Aspergillosis is one such opportunistic
infection, which can occur in immunosuppressed pa-
tients and is most commonly caused by the fungus
Aspergillus fumigatus [1].
A. fumigatus, as well as some Candida [2] and
Penicillium [3] species, produce gliotoxin a member of
the epipolythiodioxopiperazine class of fungal meta-
bolites [4]. The activity of gliotoxin is attributable
to a reactive disulfide bond component in the mo-
lecule, which can undergo redox cycling, resulting in
the production of oxygen radicals. A broad spectrum
of biological activity has been reported for gliotoxin
which include the prevention of macrophage adher-
ence, followed by the induction of apoptosis [5, 6].
Inhibition of phagocytosis by rodent macrophages and
mitotic stimulation of lymphocytes has been shown,
an effect unrelated to induction of apoptosis [7] but
which may assist fungal colonization. Other activities
associated with gliotoxin include inhibition of fungal
and bacterial growth [8] and viral replication [9]. From
a clinical perspective, gliotoxin is important since it
has been reported as being produced in tissues of
mice and turkey poults [10] following development of
invasive aspergillosis.
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Models of invasive aspergillosis were first de-
veloped in experimental murine systems [11], with
evidence suggesting that the innate mammalian im-
mune response is involved in the defence against
fungal pathogens. Key features involved in innate im-
munity are found to be homologous in insects and
vertebrates [12, 13]. The insect cellular processes such
as phagocytosis [14], production of reactive oxygen
species [15] and anti-microbial peptides, bear strong
similarity to those produced by phagocytes of mam-
mals, giving evidence of an ancient immune system
found in the ancestor of all bilaterian animals. Most
immunological data for insects have been reported
from Drosophila melanogaster [16] however in the
Greater Wax moth Galleria mellonella, various im-
munorelevant protein molecules have been described
and this system is being increasingly used as a model
for assessing the virulence of a range of microorgan-
isms [17, 18]. For example, larvae of G. mellonella
have been successfully used to evaluate the patho-
genicity of lipopolysaccharide-deficient mutants of
Pseudomonas aeruginosa [19] and a good correlation
exists between the virulence of P. aeruginosa in Gal-
leria larvae and in mice. Larvae of G. mellonella have
also been used to assess the virulence of Candida
albicans and strong agreement has been established
between the results obtained in insects and mice [20].
This paper describes the use of G. mellonella lar-
vae as a screening mechanism for testing the virulence
of A. fumigatus. Studies confirm the production of gli-
otoxin by four clinical isolates of A. fumigatus and
a single isolate of A. niger and demonstrate that G.
mellonella is more susceptible to fungal infection by
strains of Aspergillus producing elevated levels of
gliotoxin.
Material and methods
Fungal strains and culture conditions
Clinical isolates of Aspergillus fumigatus used in this
study included ATCC 26933, 16424, 13073 and 14109
(obtained from the American Type Culture Collec-
tion, Maryland, USA), one strain of Aspergillus niger
(environmental isolate) and the yeast Saccharomyces
cerevisiae YJM 128 (A gift from Dr. K. Clemons,
San Jose, USA) [20]. Aspergillus spores were grown
in Minimal Essential Medium Eagle (Sigma Aldrich
Chemical Co., Dublin, Ireland) supplemented with 5%
(v/v) Foetal Calf Serum (Sigma Aldrich) at 37 ◦C
and 200 rpm, for up to 4 days. Stocks were main-
tained on Malt Extract Agar (MEA) (Oxoid Ltd.). S.
cerevisiae was grown to stationary phase (approxim-
ately 1 × 108/ml) in YEPD broth (2% (w/v) glucose,
2% (w/v) bactopeptone (Difco), 1% (w/v) yeast ex-
tract (Oxoid) at 30 ◦C and 200 rpm. Stocks were
maintained on YEPD agar (2% (w/v) Agar, Difco).
Growth curve for Aspergillus
MEA plates containing sporulating Aspergillus cul-
tures were washed with 10 ml of 0.1% (v/v) Tween
80 (Merck) in Phosphate Buffered Saline (PBS, pH
7.2) (Sigma Aldrich) to isolate conidia. Conidia were
washed twice in sterile PBS, centrifuged (1,500 g, 5
min in a Beckman GS-6 centrifuge) and counted using
an haemocytometer. Flasks containing MEM (100 ml)
were inoculated with 1 × 105 Aspergillus conidia and
incubated at 37 ◦C and 200 rpm. A flask was removed
every 24 h and the contents filtered through a What-
man No. 1 filter in a Buchner funnel and air-dried. A
growth curve was constructed of dry fungal biomass
versus incubation time.
Characterisation of Aspergillus strains
Catalase activity of the five Aspergillus strains was
determined using Aspergillus niger catalase (Sigma
Aldrich) as a standard, the difference in absorb-
ance (A240) per unit time being a measure of the
catalase activity [21]. Elastase activity was quanti-
fied using the elastase-specific substrate N-succinyl-
alanyl-alany-prolyl-leucinep-nitroanilide (Sigma Ald-
rich) [22]. Substrate (final concentration, 2.5 mM)
was added to fungal hyphae (final concentration, 0.33
mg/ml protein) in buffer (100 mM Tris-HCl, 200 mM
NaCl, 0.05% (v/v) Triton X-100, pH 7.8) in a 96-well,
flat bottomed microtiter plate at 37 ◦C. The A405 was
read every 60 s for 10 min.
Preparation of extracts for detection of gliotoxin by
Reversed Phase-HPLC
Hyphae of Aspergillus were removed from the MEM
culture medium by filtration and an equal volume of
chloroform (Hyper Solv, BDH) added to the filtrates
(10 ml). Following continual mixing for 30 min, the
chloroform fraction was collected and evaporated to
dryness. For detection of gliotoxin, dried extracts were
dissolved in 200 µl methanol (Hyper Solv, BDH)
and stored at −70 ◦C until assayed. Gliotoxin was
detected by Reversed Phase-HPLC (Spectra-Physics).
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The mobile phase was 34.9% (v/v) acetonitrile (Hy-
per Solv, BDH), 0.1% (v/v) trifluoroacetic acid (Sigma
Aldrich) and 65% (v/v) deionized-distilled water. The
gliotoxin extract (20 µl) was injected onto a C18 Hew-
lett Packard column. A standard curve of peak area
versus gliotoxin concentration was constructed using
gliotoxin standards (50, 100 and 200 ng/ml dissolved
in methanol, (Sigma Aldrich). The amount of gli-
otoxin in the samples was calculated from the standard
curve.
Inoculation of insects with conidia of Aspergillus
Sixth instar larvae of G. mellonella were obtained
from the Meal Worm Company (Sheffield, England).
Larvae were stored in wood shavings in the dark at
15 ◦C prior to use. All larvae were used within 3 weeks
of receipt. Larvae between 0.2 and 0.4 g in weight
were employed in all assays. Larvae were injected
with 1 × 104 conidia in 20 µl PBS into the haemocoel
through the last left pro-leg as described previously
using a Myjector U-100 Insulin needle (Terumo) [17].
Larvae were placed in a sterile petri dish and incubated
in the dark at 30 ◦C. Mortality rates were determ-
ined over a 5 day period. Larval death was assessed
by the absence of movement and discolouration of
the cuticle [17, 20]. The extraction of gliotoxin from
tissue samples infected with Aspergillus was as de-
scribed by Richard et al. [10]. In brief, 100 infected
larvae were homogenized in 5 ml of H2O. The ho-
mogenizer was rinsed twice with 10 ml of 6N HCL
and pooled to give 25 ml. Chloroform (200 ml) was
added and the mixture stirred at room temperature for
30 min. The sample was poured into a separatory fun-
nel and the gliotoxin extracted in the lower chloroform
layer. Detection and quantification of gliotoxin was as
described above.
Statistical analysis
Survival of larvae after injection was analysed by
Kaplan–Meier survival analysis. Catalase and elastase
activities were analysed by Student’s two tailed t-test.
Results
Growth curves for the five Aspergillus isolates (Fig-
ure 1) showed the exponential growth phase began at
12 h and extended until 48 h. The stationary phase
Figure 1. Growth curves. Growth curve of Aspergillus isolates in
MEM at 37 ◦C, = ATCC 26933,  = A. niger, = 16424,  =
13073,  = 14109.
was reached at approximately 72 h with a greater bio-
mass being obtained for A. fumigatus ATCC 16424
(1.0mg/ml of culture).
Characterization of the different Apergillus strains
showed them to vary in enzymatic activity. Quantifica-
tion of elastase activity demonstrated that A. niger and
A. fumigatus ATCC 14109 exhibited elevated levels of
activity (25–30 U/mg hyphae), whereas isolates ATCC
26933, 16424 and 13073 produced between 10 and 20
U of elastase activity per mg of fungal hyphae (Figure
2a). Between the different Aspergillus isolates no sig-
nificant difference was found in the level of catalase
activity, with a standard level of approximately 0.25
U/min/mg hyphae activity calculated (Figure 2b).
Production of gliotoxin by A. fumigatus has pre-
viously been detected at temperatures ranging from
30 ◦C [23] to 37 ◦C [24]. The conventional method of
Reversed Phase-HPLC quantification was used for the
determination of gliotoxin production [25]. All isol-
ates of Aspergillus were found to produce gliotoxin
with production starting after 24 h (Figure 3). Strain
ATCC 26933 produced more gliotoxin than the other
4 strains of Aspergillus (350 ng/mg hyphae, P <
0.001), with maximum gliotoxin production occurring
at approximately 72 h incubation. A subsequent de-
cline in levels was observed which may have been due
to catabolism or instability of the compound.
An investigation into the pathogenicity of the five
strains of Aspergillus was performed using the G.
mellonella virulence model. Figure 4a shows the mor-
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Figure 2. Enzymatic activity. (a) Elastase activity of A. niger and
four strains of A. fumigatus. ∗∗ = no significant difference between
isolates ATCC 26933 and 16424 (P = 0.1), ∗ = significant differ-
ence between A. niger, ATCC 14109 and 13073 relative to 26933
and 16424 (P < 0.01). (b) Catalase activity of the 5 isolates of
Aspergillus (P = 0.09). All results are means ± s.e.m. from three
separate measurements.
tality of Galleria following injection with Aspergil-
lus conidia. The control, a non-virulent strain of S.
cerevisiae [17] and A. fumigatus strains ATCC 13073
and 16424 had minimal effect on larval mortality.
This was in marked contrast to the A. fumigatus strain
ATCC 14109 and A. niger which killed approximately
20% of the infected larvae within 24 h after infection
with 1 × 104 conidia.
The results reveal elevated mortality rates for lar-
vae inoculated with the clinical isolate A. fumigatus
ATCC 26933. Furthermore, within 48 h all larvae in-
oculated with this strain had been killed. This strain
was found to produce the highest levels of gliotoxin
(Figure 4b), indicating a likely correlation between
gliotoxin production and virulence in G. mellonella.
In order to establish a more direct link between gli-
otoxin production and virulence, further studies were
made on the occurrence of gliotoxin in larvae of G.
Figure 3. Quantification of gliotoxin production. Gliotoxin produc-
tion as a function of fungal hyphal biomass. All results are means
± s.e.m. from three measurements. A statistically significant differ-
ence was found for ATCC 26933 compared to all other strains at
days 2, 3 and 4 (P < 0.001).
mellonella infected with the fungus. Results showed
that the toxin was formed during growth of A. fumig-
atus, as gliotoxin was found in larvae infected with
the gliotoxin-producing strains and was not found in
tissues from healthy uninfected larvae. As depicted in
Figure 4b various levels of gliotoxin was found in G.
mellonella tissue samples following inoculation with
1 × 104 conidia of the different Aspergillus isolates.
The levels of gliotoxin ranged from 250–2400 ng/g
of insect mass; two Aspergillus isolates, ATCC 16424
and ATCC 13073 produced no detectable levels. The
highest concentration of gliotoxin detected followed
inoculation with A. fumigatus ATCC 26933 (2400
ng/g) at a time corresponding to 50% larval death
(Figure 4a). Infection with 1 × 104 A. fumigatus
ATCC 14109 or A. niger resulted in similar (250–
280 ng/g) gliotoxin concentrations. Collectively these
results indicate a likely correlation between gliotoxin
production and virulence of A. fumigatus ATCC 26933
in G. mellonella.
Discussion
The fact that there are many airborne fungi, not implic-
ated in disease suggests that A. fumigatus may produce
specific virulence factors that are important in helping
the pathogenic fungus to colonize tissue. Several lines
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Figure 4. Susceptibility of G. mellonella larvae to fungal infection.
(a) Survival probability plots (Kaplan–Meier) of larvae injected with
1 × 104 conidia of the Aspergillus isolates (n = 20). The rates of
decreased probability of survival of larvae injected with A. fumig-
atus ATCC 26933 was significantly different from all other isolates
(P < 0.05).  = ATCC 26933,  = A. niger,  = 14109,
♦ = 16424,  = 13073,  = S. cerevisiae. (b) In vivo production
of gliotoxin as a function of larval biomass. Larvae of G. mell-
onella were injected with 1 × 104 conidia of A. fumigatus ATCC
26933, 16424, 14109, 13073, and A. niger and gliotoxin production
compared to uninfected larvae (Con).
of evidence suggest a role for gliotoxin in the patho-
genesis of aspergillosis, as this metabolite is produced
by over 95% of pathogenic isolates of A. fumigatus.
Neutrophils and alveolar macrophages are the
main cellular components of the vertebrate immune
system responsible for the defence against C. albicans
[26] and A. fumigatus [27]. They eliminate patho-
gens by phagocytosis, the release of reactive oxygen
intermediates and activation of proteolytic enzymes
[26, 28]. Similar cellular processes have been de-
scribed for phagocytes of insects, with receptors on
the surface of plasmatocytes and granulocytes exhib-
iting striking similarity to receptors on mammalian
phagocytes [14]. A. fumigatus can escape local host
defences by synthesizing metabolites that inhibit these
immune defences. Müllbacher and Eichner described
the inhibition of phagocytosis by gliotoxin [6], while
others have demonstrated that gliotoxin causes mor-
phological alterations to macrophages [29]. The wax
moth G. mellonella has previously been used to test
the virulence of a variety of microorganisms [17, 18,
20] and in this study we employed G. mellonella to dif-
ferentiate between pathogenic Aspergillus species and
to determine if the production of an immunosuppress-
ive agent, such as gliotoxin, could further compromise
the infected host. On comparing the lethality of dif-
ferent strains, it should be noted that the growth rate
of each strain might have the potential to affect patho-
genesis. It was observed that the Aspergillus isolate
ATCC 16424 which possessed the fastest growth rate,
exhibited a virulence level equivalent to that of the
non-virulent isolate of S. cerevisiae [20].
Catalase is an antioxidant metalloenzyme, which
is almost ubiquitous among aerobic organisms and
protects cells against oxidative damage caused by hy-
drogen peroxide. It has been reported that oxidative
mechanisms are important in the killing of A. fumig-
atus by polymorphonuclear cells and that this fungus
is sensitive in vitro to oxygen metabolites [30]. The
catalase activities of Aspergillus isolates employed in
this study were quantified. As all isolates possessed
similar activity, an anti-virulent role for catalase in
protection against oxidative killing by reactive oxygen
intermediates produced by haemocytes cannot be as-
sessed using the particular Aspergillus strains of this
study.
It has been speculated that extracellular proteinases
play a role in virulence, by allowing tissue invasion by
fungal cells and also in resistance to phagocytic killing
by the host [31]. A number of isolates of A. fumig-
atus obtained from a hospital environment produced
extracellular elastolytic activity and immunogold loc-
alization of the elastolytic enzyme showed that A.
fumigatus germinating and penetrating into the lungs
of neutropenic mice secreted the elastolytic protease
[32]. Elastase activity of the five Aspergillus isolates
used in this study was quantified and although various
levels of activity were observed, those strains illus-
trating increased elastase activity, demonstrated low
levels of virulence as measured in G. mellonella.
Gliotoxin production by A. fumigatus has been es-
timated to be in the range of 20 to 80 µg/ml culture
after approximately 4–7 days [6] and this concentra-
tion has been shown to inhibit the growth of several
Gram-negative bacteria and fungi, and viral replica-
tion in vitro [33]. In this study A. fumigatus ATCC
26933 produced the highest concentration of gliotoxin
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(350 ng/mg of hyphae) after three days growth at
37 ◦C. Interestingly a lower concentration of gliotoxin
(20-50 ng/ml) has been shown to have an inhibitory
effect on phagocytosis of carbon particles by periton-
eal exudates [7]. An additional observation was the
detection of maximum gliotoxin production after three
days of growth in vitro with maximum larval death
occurring two days post infection. This temporal dis-
crepancy may indicate that the high concentration of
gliotoxin detected in vitro may not be required in vivo
to obtain the level of killing observed.
The results indicate the existence of a hierarchy
among the Aspergillus isolates studied here with re-
spect to their ability to kill larvae of G. mellonella,
i.e. ATCC 26933 > ATCC 14109 = A. niger >
ATCC 16424 = ATCC 13073. Consistently, Aspergil-
lus species killed larvae to a greater extent than the
non-pathogenic S. cerevisiae and the differences in re-
lative pathogenicity between the Aspergillus isolates,
in particular A. fumigatus ATCC 26933, may be ex-
plained by the increased levels of gliotoxin produced
by this isolate.
The correlation between gliotoxin production and
virulence in G. mellonella was further strengthened by
the observation of the occurrence of gliotoxin in larvae
infected with the fungus. Recoveries of gliotoxin have
been made from bovine samples and from lung tissue
of turkeys (10) inoculated via the posterior thoracic air
sac with A. fumigatus conidia, with levels of gliotoxin
ranging from 183–6849 ng/g, a concentration similar
to what was found in the Galleria tissue in this study.
Preliminary spiking studies indicated, approximately
40% of the gliotoxin was recovered from normal lar-
val tissue samples to which purified gliotoxin was
added at known concentrations, and therefore the rel-
evant adjustment in calculations were made. Relative
to the other Aspergillus strains, A. fumigatus ATCC
26933 produced higher concentrations of gliotoxin in
vivo (Figure 3) than in vitro (Figure 4b), which may
by due to the ability of this strain to produce in-
creased levels of the immunosuppressive toxin when
challenged by cells of the host immune response. In
addition, the growth environment within the larvae
may facilitate elevated gliotoxin production compared
to that in culture.
Inoculation of Galleria with similar concentrations
of purified gliotoxin did not appear to induce the
same pathogenic effect as the growing fungus (result
not shown). It is possible therefore, in cases of as-
pergillosis that the toxin produced by the fungus is
concentrated in the tissue adjacent to the colony and
assists escape from local host defences via its reported
immunosuppressive role [6, 29, 34, 35].
In conclusion, the work presented here demon-
strates differences in the virulence of clinical isolates
of Aspergillus, as detected in larvae of G. mellonella.
While the insect and mammalian immune systems dif-
fer, they share a high degree of similarity in terms of
their innate immune responses [12] which is an im-
portant line of defence against fungal infection [36].
The response of insects to infection shows strong
similarities to that found in mammals [17, 18]. The
information generated by the use of low gliotoxin
producing strains of Aspergillus, e.g. the reduced mor-
tality of larvae infected with ATCC 13073 compared
to the high mortality of larvae infected with the high
gliotoxin-producing strain ATCC 26933, suggests that
gliotoxin production is a significant contributor to
the pathogenicity of A. fumigatus in this model. We
have not excluded the presence of other factors that
may explain the difference in virulence between the
Aspergillus isolates however with the data obtained,
gliotoxin is a likely candidate, further strengthening
its role in the pathogenesis of A. fumigatus-induced
diseases.
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